Charles River Laboratories (CRL) Tops Q3 EPS by 6c

Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $0.86, $0.06 better than the analyst estimate of $0.80. Revenue for the quarter came in at $327.6 million versus the consensus estimate of $326.7 million.

Charles River Laboratories sees FY2014 EPS of $3.33-$3.38, versus prior guidance of $3.25-$3.35 and the consensus of $3.33.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• IBEX Limited (IBEX) Tops Q4 EPS by 6c; offers guidance
• RH (RH) Tops Q2 EPS by $2.31